The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Eremkina A.K.

National Medical Research Center for Endocrinology, Ministry of Health of Russia, Moscow, Russia

Dzeranova L.K.

ndokrinologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Pigarova E.K.

National Medical Research Center for Endocrinology, Ministry of Health of Russia, Moscow, Russia

Mokrysheva N.G.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Dedov I.I.

Endocrinology Research Centre

Morphofunctional features of non-functioning pituitary adenomas

Authors:

Eremkina A.K., Dzeranova L.K., Pigarova E.K., Mokrysheva N.G., Dedov I.I.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2019;81(1): 71‑78

DOI: 10.17116/patol20198101171

Read: 6577 times

Download PDF (RU)
Contact the author
Table of contents

MORPHOFUNCTIONAL FEATURES OF NON-FUNCTIONING PITUITARY ADENOMAS
MORPHOFUNCTIONAL FEATURES OF NON-FUNCTIONING PITUITARY ADENOMAS

To cite this article:

Eremkina AK, Dzeranova LK, Pigarova EK, Mokrysheva NG, Dedov II. Morphofunctional features of non-functioning pituitary adenomas. Russian Journal of Archive of Pathology. 2019;81(1):71‑78. (In Russ.)
https://doi.org/10.17116/patol20198101171

 
Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A role of transcription factors in pathogenic processes asso­ciated with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Inve­stigation of the rela­tionship of indi­vidual characteristics of the brain bioelectrical acti­vity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117
Abstract:

Non-functioning pituitary adenomas (NFPAs) account for about 30% of all pituitary tumors. NFPAs are characterized by the lack of secretory potential or its weak expression insufficient for determination of the blood level of adenohypophyseal tropic hormones and for development of a specific clinical picture. Morphologically, NFPAs are a heterogeneous group of tumors, the classification of which was previously based only on immunoreactivity for pituitary tropic hormones. The WHO revised its Classification of Tumors of Endocrine Organs (4th edition) in 2017. The main changes relate to adenohypophysial-cell lineage for the designation of adenomas into subtypes. The introduction of transcription factor antibodies has become a fundamentally new approach to the classification of NFPAs, which is necessary to recognize less differentiated tumor types. This paper provides information on the new histopathological classification of pituitary adenomas, on the theories of silent adenomas, and on the proliferative and prognostic markers of NFPAs.

Keywords:

non-functioning pituitary adenomas
silent pituitary adenomas
high-risk pituitary adenomas
aggressiveness
transcription factors
immunohistochemical analysis

Authors:

Eremkina A.K.

National Medical Research Center for Endocrinology, Ministry of Health of Russia, Moscow, Russia

Dzeranova L.K.

ndokrinologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva

Pigarova E.K.

National Medical Research Center for Endocrinology, Ministry of Health of Russia, Moscow, Russia

Mokrysheva N.G.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Dedov I.I.

Endocrinology Research Centre

Close metadata

References:

  1. Lipatenkova AK. Graniny v kachestve immunogistokhimicheskikh i biokhimicheskikh markerov gormonal’no-neaktivnykh adenom gipofiza. Diss. Moscow. 2016. (In Russ.)
  2. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocirne organs. 4th ed. Lyon: IARC; 2017.
  3. Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, et al; and the attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017;24(4):5-8. https://doi.org/10.1530/ERC-17-0004
  4. Ntali G, Wass JA. Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary. 2018;21(2):111-118. https://doi.org/10.1007/s11102-018-0869-3
  5. Mayson SE, Snyder PJ. Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol. 2014;117(3):429-436.
  6. Greenman Y, Stern N. Non-functioning pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):625-638.
  7. Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol. 2010;163(2):193-200. https://doi.org/10.1530/EJE-10-0255
  8. Sanmillan JL, Torres-Diaz A, Sanchez-Fernandez JJ, Lau R, Ciller C, Puyalto P, Gabarros A. Radiological predictors for extent of resection in pituitary adenoma surgery. A single-center study. World Neurosurg. 2017;108:436-446.
  9. Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J. Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab. 2017;102(9):3368-3374. https://doi.org/10.1210/jc.2017-00773
  10. Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab. 2012;26(4):447-460. https://doi.org/10.1016/j.beem.2012.01.002
  11. Kobayashi I, Oka H, Naritaka H, Sato Y, Fujii K, Kameya T. Expression of Pit-1 and growth hormone-releasing hormone-receptor mRNA in human pituitary adenomas: diference among functioning, silent, and other nonfunctioning adenomas. Endocr Pathol. 2002;13(2):83-98. https://doi.org/10.1385/EP:13:2:83
  12. Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol. 2017;176(2):195-201.
  13. Vallette-Kasic S, Figarella-Branger D, Grino M, Pulichino AM, Dufour H, Grisoli F, Brue T. Differential regulation of proopiomelanocortin and pituitary-restricted transcription factor (TPIT), a new marker of normal and adenomatous human corticotrophs. J Clin Endocrinol Metab. 2003;88(7):3050-3056.
  14. Tateno T, Izumiyama H, Doi M, Yoshimoto T, Shichiri M, Inoshita N, Hirata Y. Differential gene expression in ACTH-secreting and non-functioning pituitary tumors. Eur J Endocrinol. 2007;157(6):717-724. https://doi.org/10.1530/EJE-07-0428
  15. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Trouillas J. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol. 2010;163(1):35-43. https://doi.org/10.1530/EJE-10-0076
  16. Holck S, Wewer UM, Albrechtsen R. Heterogeneity of secretory granules of silent pituitary adenomas. Mod Pathol. 1988;1(3):212-215.
  17. Kontogeorgos G, Horvath E, Kovacs K. Sex-linked ultrastructural dichotomy of gonadotroph adenomas of the human pituitary: an electron microscopic analysis of 145 tumors. Ultrastruct Pathol. 1990;14(6):475-482. https://doi.org/10.3109/01913129009076134
  18. Kovacs K, Lloyd R, Horvath E, Asa SL, Stefaneanu L, Killinger DW, Smyth HS. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol. 1989;134(2):345-353.
  19. Yamada S, Sano T, Stefaneanu L, Kovacs K, Aiba T, Sawano S, Shishiba Y. Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab. 1993;76(2):352-356.
  20. Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med. 1978;64(3):492-499.
  21. Takumi I, Steiner DF, Sanno N, Teramoto A, Osamura RY. Localization of prohormone convertases 1/3 and 2 in the human pituitary gland and pituitary adenomas: analysis by immunohis- tochemistry, immunoelectron microscopy, and laser scanning microscopy. Mod Pathol. 1998;11(3):232-238.
  22. Tateno T, Izumiyama H, Doi M, Akashi T, Ohno K, Hirata Y. Defective expression of prohormone convertase 1/3 in silent corticotroph adenoma. Endocr J. 2007;54(5):777-782.
  23. Zoli M, Faustini-Fustini M, Mazzatenta D, Marucci G, De Carlo E, Bacci A, Pasquini E, Lanzino G, Frank G. ACTH adenomas transforming their clinical expression: report of 5 cases. Neurosurg Focus. 2015;38(2):E15.
  24. Righi A, Faustini-Fustini M, Morandi L, Monti V, Asioli S, Mazzatenta D, Bacci A, Foschini MP. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. Endocrine. 2017;56(2):286-297.
  25. Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg. 2005;19(1):38-42. https://doi.org/10.1080/02688690500081230
  26. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J. 2009;56(4):579-284.
  27. Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521-535. https://doi.org/10.1007/s00401-017-1769-8
  28. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, et al. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery. 2007;61(3):580-585.
  29. Young WF, Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: a clinicopathologic analysis of 100 cases. Mayo Clin Proc. 1996;71(7):649-656. https://doi.org/10.4065/71.7.649
  30. Cooper O. Silent corticotroph adenomas. Pituitary. 2015;18(2):225-231. https://doi.org/10.1007/s11102-014-0624-3
  31. Sjostedt E, Bollerslev J, Mulder J, Lindskog C, Ponten F, Casar-Borota O. A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classi cation of pituitary neuroendocrine tumours. Acta Neuropathol. 2017;134(4):675-677.
  32. Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, Laws ERJr, Young WFJr. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47(3):723-729; discussion 729-730.
  33. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010;1(2):80-92. https://doi.org/10.1007/s12672-010-0014-x
  34. Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, Blevins L, Aghi MK. A comprehensive longterm retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery. 2013;73(1):8-17; discussion 17-18.
  35. Langlois F, Lim DST, Yedinak CG, Cetas I, McCartney S, Cetas J, Dogan A, Fleseriu M. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary. 2018;21(1):32-40.
  36. Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER. Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery. 2003;53(5):1076-1085.
  37. Wade AN, Baccon J, Grady MS, Judy KD, O’Rourke DM, Snyder PJ. Clinically silent somatotroph adenomas are common. Eur J Endocrinol. 2011;165(1):39-44.
  38. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Rahman MM, Yamada S . Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19(2):82-91.
  39. Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T, Yamada S, Hirata Y. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J. 2012;59(3):221-228.
  40. Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA. Do the limits of serum prolactin in disconnection hyperprolactinaemia need redefinition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol. 2006;65(4):524-529.
  41. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the Province of Liège, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769-4775. https://doi.org/10.1210/jc.2006-1668
  42. Azzalin A, Appin CL, Schniederjan MJ, Constantin T, Ritchie JC, Veledar E, Oyesiku NM, Ioachimescu AG. Comprehensive evaluation of thyrotropinomas: single-center 20-year experience. Pituitary. 2016;19(2):183-193.
  43. Kirkman MA, Jaunmuktane Z, Brandner S, Khan AA, Powell M, Baldeweg SE. Active and silent thyroid-stimulating hormone-expressing pituitary adenomas: presenting symptoms, treatment, outcomes, and recurrence. World Neurosurg. 2014;82(6):1224-1231.
  44. Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol. 2016;29(2):131-142.
  45. Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF Jr. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxford). 2009;71(1):92-99.
  46. Kontogeorgos G, Scheithauer BW, Horvath E, Kovacs K, Lloyd RV, Smyth HS, Rologis D. Double adenomas of the pituitary: a clinicopathological study of 11 tumors. Neurosurgery. 1992;31(5):840-849.
  47. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years postoperative follow-up. Acta Neuropathol. 2013;126(1):123-135. https://doi.org/10.1007/s00401-013-1084-y
  48. Jarain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Scucchi LF, Gulino A, Cantore G. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9(2):103-113.
  49. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38:99-106; discussion 106-107.
  50. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M. Biomarkers of pituitary neoplasms: a review (part II). Neurosurgery. 2010;67(6):1790-1798; discussion 1798.
  51. Pan LX, Chen ZP, Liu YS, Zhao JH. Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol. 2005;74:71-76.
  52. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fèvre-Montange M, Rey C, Figarella-Branger D, et al. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer. 2007;14(3):887-900. https://doi.org/10.1677/ERC-07-0062
  53. Lenders N, McCormack A. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary. 2018;21(2):217-229. https://doi.org/10.1007/s11102-017-0857-z
  54. Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, Bergmann M, Knappe HU, Hans VH, Flitsch J, Saeger W, Buslei R. Histological criteria for atypical pituitary adenomas — data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun. 2015;3:50.
  55. Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95(5):2334-2342.
  56. Evang JA, Berg JP, Casar-Borota O, Lekva T, Kringen MK, Ramm-Pettersen J, Bollerslev J. Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours. Clin Endocrinol (Oxford). 2011;75(6):811-818.
  57. Zhou W, Song Y, Xu H, Zhou K, Zhang W, Chen J, Qin M, Yi H, Gustafsson JA, Yang H, Fan X. In nonfunctional pituitary adenomas, estrogen receptors and slug contribute to development of invasiveness. J Clin Endocrinol Metab. 2011;96(8):E1237-E1245.
  58. Oystese KA, Casar-Borota O, Normann KR, Zucknick M, Berg JP, Bollerslev J. Estrogen receptor alpha, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA. J Clin Endocrinol Metab. 2017;102(9):3581-3590.
  59. Dai C, Sun B, Liu X, Bao X, Feng M, Yao Y, Wei J, Deng K, Yang C, Li X, Ma W, Wang R. O-6-methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis. Oncotarget. 2017;8(12):19674-19683. https://doi.org/10.18632/oncotarget
  60. Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab. 2013;98(3):1130-1136.
  61. Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007;156(1):65-74. https://doi.org/10.1530/eje.1.02313
  62. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin-A secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89(10):5181-5188.
  63. Greenman Y, Cooper O, Yaish I, Robenshtok E, Sagiv N, Jonas-Kimchi T, Yuan X, Gertych A, Shimon I, Ram Z, Melmed S, Stern N. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol. 2016;175(1):63-72.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.